Markets· August 16, 2026 at 09:01 p.m.
Avita Medical Aims for Q4 2025 Cash Flow Breakeven as Revenue Grows
Key takeaways
- Avita Medical raised its 2025 revenue guidance
- The company aims to reach cash flow breakeven in Q4 2025
- Avita Medical's portfolio includes RECELL, Cohealyx, and PermeaDerm
Avita Medical Inc., a regenerative medicine company, has raised its 2025 revenue guidance to $86 million–$89 million. The company expects to reach cash flow breakeven in Q4 2025, supported by declining cash use, stable operating expenses and margins, and $11 million in cash available at the end of Q2. Avita Medical's President and CEO Cary Vance made these announcements at the Canaccord 46th Annual Boston Growth Conference.
